Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RAD51B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RAD51B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RAD51B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RAD51B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RAD51B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RAD51B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RAD51B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578712 | Lung | MIAC | positive regulation of cell cycle | 28/967 | 313/18723 | 3.42e-03 | 4.43e-02 | 28 |
GO:190198711 | Lung | MIAC | regulation of cell cycle phase transition | 33/967 | 390/18723 | 3.79e-03 | 4.68e-02 | 33 |
GO:000170110 | Prostate | BPH | in utero embryonic development | 104/3107 | 367/18723 | 9.17e-09 | 3.10e-07 | 104 |
GO:00447727 | Prostate | BPH | mitotic cell cycle phase transition | 112/3107 | 424/18723 | 1.57e-07 | 3.58e-06 | 112 |
GO:00073468 | Prostate | BPH | regulation of mitotic cell cycle | 115/3107 | 457/18723 | 1.52e-06 | 2.62e-05 | 115 |
GO:00459318 | Prostate | BPH | positive regulation of mitotic cell cycle | 40/3107 | 121/18723 | 6.71e-06 | 9.70e-05 | 40 |
GO:00457878 | Prostate | BPH | positive regulation of cell cycle | 81/3107 | 313/18723 | 1.76e-05 | 2.18e-04 | 81 |
GO:19019904 | Prostate | BPH | regulation of mitotic cell cycle phase transition | 77/3107 | 299/18723 | 3.36e-05 | 3.77e-04 | 77 |
GO:19019894 | Prostate | BPH | positive regulation of cell cycle phase transition | 33/3107 | 115/18723 | 7.98e-04 | 5.23e-03 | 33 |
GO:19019874 | Prostate | BPH | regulation of cell cycle phase transition | 89/3107 | 390/18723 | 8.17e-04 | 5.34e-03 | 89 |
GO:19019923 | Prostate | BPH | positive regulation of mitotic cell cycle phase transition | 28/3107 | 93/18723 | 8.54e-04 | 5.53e-03 | 28 |
GO:00900687 | Prostate | BPH | positive regulation of cell cycle process | 58/3107 | 236/18723 | 1.03e-03 | 6.46e-03 | 58 |
GO:00018242 | Prostate | BPH | blastocyst development | 28/3107 | 106/18723 | 6.86e-03 | 3.08e-02 | 28 |
GO:000170120 | Skin | AK | in utero embryonic development | 75/1910 | 367/18723 | 3.09e-09 | 2.62e-07 | 75 |
GO:004477210 | Skin | AK | mitotic cell cycle phase transition | 83/1910 | 424/18723 | 3.81e-09 | 3.05e-07 | 83 |
GO:000734616 | Skin | AK | regulation of mitotic cell cycle | 87/1910 | 457/18723 | 6.50e-09 | 4.47e-07 | 87 |
GO:19019907 | Skin | AK | regulation of mitotic cell cycle phase transition | 57/1910 | 299/18723 | 2.47e-06 | 6.76e-05 | 57 |
GO:19019877 | Skin | AK | regulation of cell cycle phase transition | 69/1910 | 390/18723 | 3.69e-06 | 9.11e-05 | 69 |
GO:004578716 | Skin | AK | positive regulation of cell cycle | 58/1910 | 313/18723 | 5.08e-06 | 1.19e-04 | 58 |
GO:004593117 | Skin | AK | positive regulation of mitotic cell cycle | 28/1910 | 121/18723 | 2.62e-05 | 4.65e-04 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD51B | SNV | Missense_Mutation | | c.751N>G | p.Ile251Val | p.I251V | | protein_coding | tolerated(0.05) | benign(0.207) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD51B | SNV | Missense_Mutation | | c.189N>T | p.Lys63Asn | p.K63N | | protein_coding | tolerated(0.11) | benign(0.422) | TCGA-EW-A1IX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD |
RAD51B | deletion | Frame_Shift_Del | novel | c.1197_1200delAACT | p.Thr400SerfsTer29 | p.T400Sfs*29 | | protein_coding | | | TCGA-DG-A2KJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAD51B | SNV | Missense_Mutation | | c.982G>T | p.Ala328Ser | p.A328S | | protein_coding | tolerated(0.45) | possibly_damaging(0.451) | TCGA-AA-A02J-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
RAD51B | SNV | Missense_Mutation | novel | c.120G>T | p.Lys40Asn | p.K40N | | protein_coding | deleterious(0.03) | benign(0.316) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RAD51B | SNV | Missense_Mutation | | c.111N>T | p.Glu37Asp | p.E37D | | protein_coding | tolerated(0.17) | benign(0.263) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAD51B | SNV | Missense_Mutation | novel | c.653A>C | p.Lys218Thr | p.K218T | | protein_coding | tolerated(0.11) | benign(0.285) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAD51B | SNV | Missense_Mutation | novel | c.521N>T | p.Ser174Ile | p.S174I | | protein_coding | deleterious(0.01) | benign(0.029) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
RAD51B | SNV | Missense_Mutation | novel | c.578A>C | p.Glu193Ala | p.E193A | | protein_coding | deleterious(0.02) | benign(0.238) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
RAD51B | SNV | Missense_Mutation | novel | c.398N>A | p.Gly133Glu | p.G133E | | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |